Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552027 | 0.86 | S1PR1 (0.46) | S1PR1S1PR5S1PR3S1PR4CACNA2D1 | |
| SCHEMBL3559264 | 0.82 | S1PR1 (0.42) | S1PR1S1PR5S1PR3S1PR4CACNA2D1 | |
| SCHEMBL3561840 | 0.82 | S1PR1 (0.46) | S1PR1S1PR5S1PR3S1PR4CACNA2D1 | |
| SCHEMBL3560054 | 0.81 | S1PR1 (0.45) | S1PR1S1PR5S1PR3S1PR4CACNA2D1 | |
| SCHEMBL3561557 | 0.78 | S1PR1 (0.44) | S1PR1S1PR5S1PR3S1PR4CACNA2D1 | |
| SCHEMBL3554644 | 0.78 | S1PR1 (0.53) | S1PR1S1PR5S1PR3S1PR4CACNA2D1 | |
| SCHEMBL3560455 | 0.78 | S1PR1 (0.54) | S1PR1S1PR5S1PR3S1PR4KMO | |
| SCHEMBL3552779 | 0.78 | S1PR1 (0.55) | S1PR1S1PR5S1PR3S1PR4DRD2 | |
| SCHEMBL3559168 | 0.78 | S1PR1 (0.44) | S1PR1S1PR5S1PR3S1PR4DRD3 | |
| SCHEMBL3553509 | 0.75 | S1PR1 (0.46) | S1PR1S1PR5S1PR3S1PR4PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | claimed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | claimed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007109330-A2 | S1P RECEPTOR MODULATING COMPOUNDS | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR5 3/4885S1PR3 4/4885 |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR5 3/4885S1PR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.